Stéphane Bouchet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stéphane Bouchet has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Nicolas Venisse
Université de Poitiers, Ecologie Biologie des Interaction, Poitiers
3 shared publications - Alexandre Destere
Department of Clinical Pharmacology, University Hospital Centre Nice Pasteur Hospital, 06000 Nice, France; Université Côte d’Azur, Inria, CNRS, Laboratoire J.A. Dieudonné, Maasai team, 06000 Nice, France
2 shared publications - Caroline Solas
Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie, Marseille, France
2 shared publications - Florian Lemaitre
Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) – UMR_S 1085, F-35000 Rennes, France
2 shared publications - Gilles Peytavin
AP-HP Nord, Pharmacology Department, Bichat Claude-Bernard University Hospital, Paris, France
2 shared publications - Jennifer Lagoutte-Renosi
Université Marie et Louis Pasteur, CHU Besançon, SINERGIES (UR 4662), Besançon, France
2 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (6) , e70180
External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV ‐Infected Patients
Cabotegravir (CAB), combined with rilpivirine, is the first long‐acting injectable therapy approved for HIV‐1 maintenance treatment. While adherence and patient satisfaction have been improved, pharmacokinetic (PK) variability remains a concern. Two population PK models have been developed: one based on data from phase I–III trials and the other on routine clinical data. However, neither model has undergone thorough external evaluation. The aim of this study was to evaluate the predictive performance of these models using an independent prospective dataset to evaluate their suitability to support model‐informed precision dosing (MIPD). External validation was performed using data from the French observational and multicenter ( n = 14) ANRS0255 CARLAPOP study (736 HIV‐infected patients, representing 2192 concentrations). Models were implemented using MONOLIX software and evaluated using goodness‐of‐fit, prediction‐based, and simulation‐based diagnostics. For Han's model, regarding plasma concentrations following intramuscular administration, Median Prediction Error (MDPE) was −1.2% (PRED) and −4.4% (IPRED); Median Absolute Prediction Error (MDAPE) was 36.6% (PRED) and 17.9% (IPRED). For Thoueille's model, MDPE was −24.2% (PRED) and −9.2% (IPRED); MDAPE was 39.0% (PRED) and 15.3% (IPRED). However, < 70% of predictions were within a 20% error margin with both models. Graphical analyses of Thoueille's model showed systemic bias, particularly in women, nonsmokers, and patients with higher body mass index. Therefore, neither model was considered reliable enough for MIPD application in our population. Although Han et al.'s model demonstrated higher predictive performances, further improvements are required before it can be reliably applied for MIPD in daily routine.
- 22 May 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (6) , e70180
Open AccessExternal Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV ‐Infected Patients
Cabotegravir (CAB), combined with rilpivirine, is the first long‐acting injectable therapy approved for HIV‐1 maintenance treatment. While adherence and patient satisfaction have been improved, pharmacokinetic (PK) variability remains a concern. Two population PK models have been developed: one based on data from phase I–III trials and the other on routine clinical data. However, neither model has undergone thorough external evaluation. The aim of this study was to evaluate the predictive performance of these models using an independent prospective dataset to evaluate their suitability to support model‐informed precision dosing (MIPD). External validation was performed using data from the French observational and multicenter ( n = 14) ANRS0255 CARLAPOP study (736 HIV‐infected patients, representing 2192 concentrations). Models were implemented using MONOLIX software and evaluated using goodness‐of‐fit, prediction‐based, and simulation‐based diagnostics. For Han's model, regarding plasma concentrations following intramuscular administration, Median Prediction Error (MDPE) was −1.2% (PRED) and −4.4% (IPRED); Median Absolute Prediction Error (MDAPE) was 36.6% (PRED) and 17.9% (IPRED). For Thoueille's model, MDPE was −24.2% (PRED) and −9.2% (IPRED); MDAPE was 39.0% (PRED) and 15.3% (IPRED). However, < 70% of predictions were within a 20% error margin with both models. Graphical analyses of Thoueille's model showed systemic bias, particularly in women, nonsmokers, and patients with higher body mass index. Therefore, neither model was considered reliable enough for MIPD application in our population. Although Han et al.'s model demonstrated higher predictive performances, further improvements are required before it can be reliably applied for MIPD in daily routine.
- 18 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (1) , 109-118
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
Background: The impact of pharmacokinetic variability of cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) injectable therapy on virological outcomes remains controversial. This study aimed to characterize the variability of CAB and RPV trough concentrations (Ctrough) and to identify the predictors of suboptimal exposure and virologic failure (VF) in a large real-world cohort. Methods: We conducted a multicenter observational study including people with human immunodeficiency virus type 1 (HIV-1) initiating LA-CAB/RPV as maintenance therapy from January to December 2022, in whom CAB and RPV plasma Ctrough were determined as part of therapeutic drug monitoring (TDM). Results: A total of 1674 CAB and 1687 RPV Ctrough measurements were collected from 736 people with HIV-1 (PWH). Significant interindividual variability in concentrations was observed. At month 1/month 3, 20%–30% of PWH had Ctrough <1120 ng/mL for CAB and 32 ng/mL for RPV. Predictors of lower Ctrough were body mass index (BMI) ≥30 kg/m2 and female sex at month 1, and only male sex at steady state. After a median follow-up of 12 (interquartile range, 9–16) months, VF occurred in 2.5% of PWH. At month 6 and month 12, VF was significantly associated with the presence of at least 2 risk factors (obesity, suboptimal Ctrough) (odds ratio [OR], 4.6, P = .047; OR, 5.15, P = .014), and CD4 nadir (OR, 0.56, P = .008; OR, 0.5, P = .001). Conclusions: Our large real-world study confirms significant variability in CAB and RPV exposure, with BMI and sex as key predictors of lower Ctrough. Suboptimal CAB and RPV Ctrough, particularly in people with obesity, increases the risk of VF during the first year of treatment, highlighting the usefulness of TDM in clinical practice.
- 18 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (1) , 109-118
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
Background: The impact of pharmacokinetic variability of cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) injectable therapy on virological outcomes remains controversial. This study aimed to characterize the variability of CAB and RPV trough concentrations (Ctrough) and to identify the predictors of suboptimal exposure and virologic failure (VF) in a large real-world cohort. Methods: We conducted a multicenter observational study including people with human immunodeficiency virus type 1 (HIV-1) initiating LA-CAB/RPV as maintenance therapy from January to December 2022, in whom CAB and RPV plasma Ctrough were determined as part of therapeutic drug monitoring (TDM). Results: A total of 1674 CAB and 1687 RPV Ctrough measurements were collected from 736 people with HIV-1 (PWH). Significant interindividual variability in concentrations was observed. At month 1/month 3, 20%–30% of PWH had Ctrough <1120 ng/mL for CAB and 32 ng/mL for RPV. Predictors of lower Ctrough were body mass index (BMI) ≥30 kg/m2 and female sex at month 1, and only male sex at steady state. After a median follow-up of 12 (interquartile range, 9–16) months, VF occurred in 2.5% of PWH. At month 6 and month 12, VF was significantly associated with the presence of at least 2 risk factors (obesity, suboptimal Ctrough) (odds ratio [OR], 4.6, P = .047; OR, 5.15, P = .014), and CD4 nadir (OR, 0.56, P = .008; OR, 0.5, P = .001). Conclusions: Our large real-world study confirms significant variability in CAB and RPV exposure, with BMI and sex as key predictors of lower Ctrough. Suboptimal CAB and RPV Ctrough, particularly in people with obesity, increases the risk of VF during the first year of treatment, highlighting the usefulness of TDM in clinical practice.
- Open Access
- 1 May 2021
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 38 (5) , 466-476
Aspergillose bronchopulmonaire allergique (ABPA) et mucoviscidose : mécanismes, diagnostic et alternatives thérapeutiques
- 1 May 2021
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 38 (5) , 466-476
Open AccessAspergillose bronchopulmonaire allergique (ABPA) et mucoviscidose : mécanismes, diagnostic et alternatives thérapeutiques
- 1 September 2020
- Published by Elsevier in Antiviral Research
- Vol. 181, 104866
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
- 1 September 2020
- Published by Elsevier in Antiviral Research
- Vol. 181, 104866
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection